PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 17327694-0 2007 Simvastatin reduces insulin-like growth factor-1 signaling in differentiating C2C12 mouse myoblast cells in an HMG-CoA reductase inhibition-independent manner. Simvastatin 0-11 insulin-like growth factor 1 Mus musculus 20-48 17327694-2 2007 In this study, we investigated the effects of simvastatin, an HMG-CoA reductase inhibitor, on the viability and insulin-like growth factor-1 (IGF-1) signaling in differentiating C2C12 mouse myoblast cells. Simvastatin 46-57 insulin-like growth factor 1 Mus musculus 112-140 17327694-2 2007 In this study, we investigated the effects of simvastatin, an HMG-CoA reductase inhibitor, on the viability and insulin-like growth factor-1 (IGF-1) signaling in differentiating C2C12 mouse myoblast cells. Simvastatin 46-57 insulin-like growth factor 1 Mus musculus 142-147 17327694-6 2007 After induction of differentiation in the presence of 1 microM simvastatin for 2 days, IGF-1-induced activation of ERK1/2 and Akt was significantly decreased. Simvastatin 63-74 insulin-like growth factor 1 Mus musculus 87-92 17327694-7 2007 Although mRNA expression of the IGF-1 receptor beta-chain (IGF-1R beta) did not change, protein level of the 200 kDa IGF-1Rbeta precursor was significantly increased by simvastatin in a dose-dependent manner. Simvastatin 169-180 insulin-like growth factor 1 Mus musculus 32-37 17327694-9 2007 These results suggest that simvastatin decreases IGF-1 signaling via a regulation of the post-translational modification of IGF-1Rbeta in an HMG-CoA reductase inhibition-independent manner. Simvastatin 27-38 insulin-like growth factor 1 Mus musculus 49-54 21839782-10 2011 These results suggest that disruption of Igf-1/Akt signaling is a causative factor in simvastatin-induced mitochondrial dysfunction in C2C12 myotubes, whereas HepG2 cells are protected by maintaining Igf-1/Akt signaling. Simvastatin 86-97 insulin-like growth factor 1 Mus musculus 41-46 27734117-0 2017 IGF-1 prevents simvastatin-induced myotoxicity in C2C12 myotubes. Simvastatin 15-26 insulin-like growth factor 1 Mus musculus 0-5 27734117-5 2017 C2C12 mouse myotubes were exposed to 10 muM simvastatin and/or 10 ng/mL IGF-1 for 18 h. Simvastatin inhibited the IGF-1/AKT signaling pathway, resulting in increased breakdown of myofibrillar proteins, impaired protein synthesis and increased apoptosis. Simvastatin 44-55 insulin-like growth factor 1 Mus musculus 114-119 27734117-5 2017 C2C12 mouse myotubes were exposed to 10 muM simvastatin and/or 10 ng/mL IGF-1 for 18 h. Simvastatin inhibited the IGF-1/AKT signaling pathway, resulting in increased breakdown of myofibrillar proteins, impaired protein synthesis and increased apoptosis. Simvastatin 88-99 insulin-like growth factor 1 Mus musculus 72-77 27734117-5 2017 C2C12 mouse myotubes were exposed to 10 muM simvastatin and/or 10 ng/mL IGF-1 for 18 h. Simvastatin inhibited the IGF-1/AKT signaling pathway, resulting in increased breakdown of myofibrillar proteins, impaired protein synthesis and increased apoptosis. Simvastatin 88-99 insulin-like growth factor 1 Mus musculus 114-119 27734117-7 2017 In addition, simvastatin impaired stimulation of AKT T308 phosphorylation by IGF-1, indicating reduced activation of the IGF-1R/PI3K pathway by IGF-1. Simvastatin 13-24 insulin-like growth factor 1 Mus musculus 77-82 27734117-7 2017 In addition, simvastatin impaired stimulation of AKT T308 phosphorylation by IGF-1, indicating reduced activation of the IGF-1R/PI3K pathway by IGF-1. Simvastatin 13-24 insulin-like growth factor 1 Mus musculus 121-126 27734117-8 2017 Nevertheless, simvastatin-induced myotoxicity could be at least partially prevented by IGF-1. Simvastatin 14-25 insulin-like growth factor 1 Mus musculus 87-92 27734117-13 2017 IGF-1 can prevent simvastatin-associated cytotoxicity and metabolic effects on C2C12 cells. Simvastatin 18-29 insulin-like growth factor 1 Mus musculus 0-5